Viracta Therapeutics, Inc. Profile Avatar - Palmy Investing

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase…

Biotechnology
US, Cardiff-by-the-Sea [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of VIRX's Analysis
CIK: 1061027 CUSIP: 92765F108 ISIN: US92765F1084 LEI: - UEI: -
Secondary Listings
VIRX has no secondary listings inside our databases.